Strategic partnerships Voyager maintains a diversified partner ecosystem including Alexion, AstraZeneca Rare Disease, Novartis, and Neurocrine Biosciences, presenting multiple co-development and licensing sales opportunities to expand reach across neurological indications.

Tau therapy momentum VY1706 targeting intracellular and extracellular tau for Alzheimer's disease has recent GLP toxicology data and AAIC presentations, signaling a strong near-term opportunity for collaboration in tau-focused gene therapy or related delivery platforms.

TRACER platform value The TRACER AAV capsid discovery platform enables high brain penetration and potential scalable manufacturing advantages, making Voyager an attractive partner for superior CNS delivery capabilities and joint development programs.

Financial health signals With substantial revenue and additional funding alongside ongoing investor-facing events, Voyager appears equipped to support expanded clinical programs and co-funded initiatives with strategic partners.

Industry engagement Active participation in ASGCT and AAIC conferences, plus ongoing investor communications, indicates a proactive external engagement strategy ideal for identifying collaboration opportunities, joint ventures, and licensing deals with mid- to large-cap biotech and pharma buyers.